Caplin Point Laboratories’ Profit Up by 20.7% in June Quarter

Chennai, August 7, 2025: Caplin Point Laboratories has announced strong financial results for the first quarter of the year. The company’s profit after tax saw a significant rise of 20.7% compared to the same period last year.

Furthermore, the company has announced a final dividend of ₹3 per share, which is a 150% payout on a face value of ₹2. This is in addition to the ₹3 interim dividend that was already paid in June. This brings the total dividend for FY25 to ₹6 per share, or 300%, which is subject to shareholder approval at the upcoming Annual General Meeting (AGM) on September 22, 2025.

The company’s stock closed the day today up by 4.74% at Rs 2,021.

Caplin Point Laboratories Ltd, listed on the NSE as CAPLIPOINT and on the BSE as 524742, is a fully integrated pharmaceutical company. It holds a leadership position in Latin America and is increasing its presence in regulated markets such as the US, Canada, and Australia. The company has manufacturing and R&D facilities in Tamil Nadu, Puducherry, and Andhra Pradesh and has been recognised multiple times on Forbes Asia’s 200 Best Under a Billion list.

Insights For Investors

• Strong and Steady Growth: Caplin Point has delivered a solid Q1FY26 performance with a 20.7% rise in profit after tax and double-digit revenue growth. This shows the company’s strong demand and operational efficiency, especially in international markets.
• Healthy Dividend Payout: The total dividend of ₹6 per share for FY25 (₹3 interim + ₹3 final) reflects the company’s strong cash flows and investor-friendly approach. At a face value of ₹2, this 300% payout signals consistent rewards to shareholders.
• Global Presence Driving Revenue: Around 79% of the company’s revenue comes from emerging markets like Latin America and Africa. Its US operations are also picking up, contributing 20% to total revenue – showing diversification and growing presence in regulated markets.
• Future-Focused Investments: The ongoing investment of over ₹1,000 crore in new manufacturing facilities, especially for high-growth segments like oncology and APIs, indicates long-term planning for capacity expansion and margin improvement.
• Innovative Expansion Plans: Caplin’s “China 2.0” strategy and its growing US subsidiary point to a tech-forward, global growth model. This may boost investor confidence in the company’s ability to tap future pharma trends.
• Valuation Support from EPS Growth: With a 23.1% YoY rise in EPS to ₹20.10, the company continues to improve shareholder value, which may support further upside in stock price.

In summary, Caplin Point offers a mix of consistent earnings growth, strong global market exposure, and strategic expansion.

Key Financial Highlights: Q1FY26 (Consolidated)

For the quarter, the company’s revenue from operations was ₹510.22 crore, which is an 11.2% growth compared to ₹458.96 crore in the same quarter last year and a 1.5% rise from ₹502.45 crore in the previous quarter. The total revenue followed a similar trend, reaching ₹533.36 crore, an 11.7% increase from ₹477.52 crore last year and a 1.0% increase from ₹528.19 crore in the last quarter. The gross profit for the quarter stood at ₹315 crore, a 15.2% increase from ₹273.48 crore year-on-year and a 4.6% rise from ₹301.25 crore quarter-on-quarter.

The company’s EBITDA grew by 17.9% to ₹200.90 crore, up from ₹170.37 crore last year and 3.7% from ₹193.80 crore in the previous quarter. The profit before tax saw a 19.5% increase to ₹184.46 crore compared to ₹154.38 crore a year ago, and a 4.4% rise from ₹176.67 crore in Q4 FY25. The profit after tax reached ₹150.76 crore, a healthy 20.7% increase from ₹124.92 crore year-on-year, and a 3.8% increase from ₹145.28 crore quarter-on-quarter. The basic EPS also rose significantly by 23.1% to ₹20.10 from ₹16.32 last year.

Segment-Wise Revenue Contribution

Caplin Point generates most of its revenue from markets outside of the US. In Q1 FY26, the Rest of the World segment, which includes emerging markets in Latin America and Africa, contributed ₹403.53 crore, accounting for approximately 76% of the total revenue. The US market showed strong growth, with revenue reaching ₹106.69 crore, making up about 20% of the total. The company’s overall revenue from emerging markets is about 79%.

Strategic Developments

Caplin Point is currently investing over ₹1,000 crore in new manufacturing projects, with half of them nearing completion. These projects include new facilities for oncology API and injectables in Tamil Nadu and a general API unit in Visakhapatnam. The company is also expanding its presence in Latin America with a new warehouse in Chile, where it already has over 120 product registrations. In the US, its subsidiary, CSL USA, has been performing well, generating $3.2 million in revenue in just eight months and acquiring a customer base of 5,610 end users. The company also has a new “China 2.0” strategy to expand into high-tech products like biosimilars and peptides.

Management Commentary

“We’re putting in place the right building blocks for both emerging and regulated markets,” said Mr. C.C. Paarthipan, Chairman. “We’re aiming to gradually onshore strategic manufacturing and expand deeper into key target markets like Mexico, Chile, and the US. Our second innings from China will focus on high-tech products like biosimilars and peptides.”

What’s Ahead For Caplin Point?

Cash Ur Drive Marketing is now a listed company and is in a good position to grow. It earns money by putting ads on vehicles and public places like EV charging stations and airports. The company has shown strong profit growth and has very little debt, which is a good sign for investors. With the money raised from the IPO, it plans to expand to more cities and increase its services. If it keeps doing well, it may attract more investors in the future. However, since it’s newly listed, its share price may go up and down in the short term.

REF: https://nsearchives.nseindia.com/corporate/CAPLINPOINT_07082025124951_Outcome_07082025_SD.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations